<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>To study the pathogenesis of Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, we introduced activated c-myc genes into human EBV-infected lymphoblastoid cells derived from in vitro <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> of <z:mpath ids='MPATH_458'>normal</z:mpath> cord blood or directly from infected peripheral blood from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e> patients </plain></SENT>
<SENT sid="1" pm="."><plain>In both cell types the constitutive expression of exogenous c-myc caused negative regulation of endogenous c-myc expression, changes in growth properties typical of transformed cells, and acquisition of tumorigenicity in immunodeficient mice </plain></SENT>
<SENT sid="2" pm="."><plain>In <z:hpo ids='HP_0000001'>all</z:hpo> myc-transfected populations the degree of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> directly correlated with the level of c-myc <z:chebi fb="2" ids="33699">mRNA</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain><z:e sem="disease" ids="C0149678" disease_type="Disease or Syndrome" abbrv="">EBV infection</z:e> and c-myc activation are thus sufficient for the tumorigenic conversion of human B cells in vitro, strongly supporting the hypothesis that these same two pathogenetic steps may be involved in the in vivo development of Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
</text></document>